Compare General Dynamics Corporation (GD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Sana Biotechnology Inc — how do they compare? General Dynamics Corporation trades at $331.24 (market cap $89.26B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: General Dynamics Corporation is far larger — about 106.7× Sana Biotechnology Inc's market cap, and General Dynamics Corporation pays a 1.93% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Sana Biotechnology Inc for 23 Days on average.
| GD | SANA | |
|---|---|---|
Market Cap | $89.26B | $836.71M |
Volume | 1,496,273 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $395.97 | $5.92 |
52-Week Low | $312.53 | $2.68 |
Typical Hold Time | 85 Days | 23 Days |
Enterprise Value | $94.40B | $749.96M |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $331.77, up 1.57% today, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q3 2026 expected at $4.14. Revenue grew to $52.55B in 2025, and net income margin improved to 8.18%. Analyst consensus is bullish with a $420.57 price target, supported by defense budget tailwinds and dividend stability.
The outlook remains positive due to robust Pentagon spending and contract visibility, though technical weakness near support at $320 poses short-term risk. Long-term growth is underpinned by submarine and vehicle demand, but investors face volatility from defense budget cycles and geopolitical uncertainties. The stock offers value with a P/E of 20.12 and a sustainable dividend.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
